Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4607]

AACR 2015: CART-meso immunotherapy feasible for patients with advanced cancers

AACR 2015: CART-meso immunotherapy feasible for patients with advanced cancers

AACR 2015: New immunotherapy yields long-lasting responses in some patients with advanced melanoma

AACR 2015: New immunotherapy yields long-lasting responses in some patients with advanced melanoma

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

AACR 2015: Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

AACR 2015: Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

A quarter of advanced lung cancer patients still not tested for EGFR mutations

A quarter of advanced lung cancer patients still not tested for EGFR mutations

Evidence grows that melanoma drugs benefit some lung cancer patients

Evidence grows that melanoma drugs benefit some lung cancer patients

Scientists discover protein that boosts immunity to viruses and cancer

Scientists discover protein that boosts immunity to viruses and cancer

New assay helps determine lymphoma subtypes simply, quickly, and inexpensively

New assay helps determine lymphoma subtypes simply, quickly, and inexpensively

Methylcytosine dioxygenase TET1 is a haematopoietic tumour repressor

Methylcytosine dioxygenase TET1 is a haematopoietic tumour repressor

More from ecancer